Blood test could predict esophageal cancer return
NCT ID NCT05704530
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study is looking at whether a blood test (liquid biopsy) can find tiny bits of cancer DNA left behind after treatment for esophageal cancer. Researchers will collect blood samples from 248 patients before, during, and after standard treatment. The goal is to see if this test can improve cancer staging and predict if the cancer will come back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Delta
RECRUITINGRoeselare, Belgium
Contact
Contact
-
UZ Gent
RECRUITINGGhent, Belgium
Contact
-
UZA
RECRUITINGAntwerp, Belgium
Contact
-
UZLeuven
RECRUITINGLeuven, Belgium
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blood sample (liquid biopsy for ctDNA)
What this could lead to
If successful, this could lead to a more accurate way to stage esophageal cancer and predict if the cancer will come back after treatment.
What could go wrong
This is an early-stage observational study, so it may not prove that liquid biopsies improve outcomes. The test might not be sensitive enough to detect all cases of residual cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.